Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 | P14416 | 5/20 | 0.60 |
| ▸ | HTR1A | P08908 | 4/20 | 0.60 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.52 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.52 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.51 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.51 |
| ▸ | NAPRT | Q6XQN6 | 1/20 | 0.50 |
| ▸ | MEN1 | O00255 | 1/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.49 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.49 |
| ▸ | DRD4 | P21917 | 1/20 | 0.48 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4183633 | 0.85 | KDM4E (0.70) | DRD2HTR1AKDM4EALDH1A1ALOX15 | |
| SCHEMBL4168265 | 0.83 | SLC6A3 (0.59) | DRD2HTR1ASLC6A3DRD4SIGMAR1 | |
| Bromide SCHEMBL4171916 | 0.82 | SLC6A3 (0.58) | DRD2HTR1ASLC6A3DRD4SIGMAR1 | |
| SCHEMBL4166707 | 0.79 | CHRNB2 (0.66) | KDM4EALDH1A1 | |
| SCHEMBL4176971 | 0.79 | TSHR (0.64) | DRD2HTR1AKDM4EALDH1A1ALOX15 | |
| SCHEMBL4169559 | 0.78 | SIGMAR1 (0.67) | KDM4EALDH1A1ALOX15SIGMAR1 | |
| Bromide SCHEMBL4166152 | 0.78 | CHRNB2 (0.64) | KDM4EALDH1A1 | |
| SCHEMBL4377443 | 0.78 | TRPV6 (0.52) | KDM4EALDH1A1NAPRTMEN1KMT2A | |
| Bromide SCHEMBL4174825 | 0.77 | SIGMAR1 (0.65) | KDM4EALDH1A1ALOX15SIGMAR1 | |
| SCHEMBL27138554 | 0.76 | MEN1 (0.64) | DRD2HTR1ASLC6A3MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090018118-A1 | HETEROCYCLIC COMPOUNDS | LEK PHARMACEUTICALS D.D. (SI) | 2009-01-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090018118-A1 | HETEROCYCLIC COMPOUNDS | CYP51A1, DHCR7, LSS | DRD2 3241/4885HTR1A 2221/4885KDM4E 2461/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.